Essential answer
The short answer
Some peptide medicines are FDA-approved for weight management in specific groups. Some are still being studied. Others do not have reliable evidence from studies in people.
01
Start with three different product groups.
The main groups are approved medicines, products still in research, and products sold without good proof. Keep these groups separate before you compare benefits or risks.
Read the full guideOpen the remaining sections and evidence limits.
01 · Continued
Start with three different product groups.: more detail
Some products are investigational. This means researchers are still testing them. They do not have FDA approval for sale in the United States. Other peptides are sold for fat loss even though good studies in people are missing, indirect, or negative. Useful studies measure changes that help people feel, function, or live longer.
FDA-approved products include Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide). Their labels cover people with obesity. They also cover some people with overweight and a related health problem. Each product has its own label. Imcivree (setmelanotide) is only for the rare obesity groups named in its label. It is not a general obesity medicine.
Researchers are still studying retatrutide and cagrilintide. Both have results from studies in people. FDA says neither peptide is part of an approved drug. FDA has not found either one safe and effective for any condition. AOD-9604, CJC-1295, ipamorelin, and MOTS-c have different evidence. Weight-loss claims for them go beyond proven results in people. FDA has also found major evidence or safety gaps for compounded versions.
This is an evidence map, not a treatment guide. It does not tell you which product is right for you. It does not provide dosing, sourcing, injection, or combination instructions.
02
Why the same ingredient name can mean different products.
The same name can describe an approved product, trial material, a compounded drug, a research vial, or a supplement. A pharmacy can compound for one named patient. An outsourcing facility can make batches under different federal rules. These products do not share the same controls, review, or evidence.
FDA approves a specific product and use, not an ingredient name. A formulation is the product's ingredients and form. A route is how it enters the body. Semaglutide and tirzepatide products do not share one universal label. The study group, result, safety limits, and follow-up rules also define the reviewed product.
That is why “semaglutide is approved” is incomplete. Ask which product, form, approved use, and group of people. An approved use is also called an indication. Use this check when a page says “the same active ingredient,” calls a compounded drug generic, or uses a trial to promote another product.
A change in the body does not prove a benefit to patients. A matching name does not prove two products are equal. A product being studied still has incomplete evidence and FDA review.
03
Approved medicines: four products with different uses.
The labels state that Wegovy, Zepbound, and Saxenda are used with a reduced-calorie diet and more physical activity. Their products, patient groups, and safety risks differ.
Semaglutide is the active ingredient in Wegovy. The June 2026 label covers injection and tablet forms. Their labeled groups differ. The injection is approved for long-term weight reduction in adults and patients aged 12 years and older with obesity. It is also approved for adults with overweight and a weight-related condition.
The tablets have weight-reduction uses for adults. The label also has separate uses for heart and liver disease. Those uses have their own limits. Do not present them as benefits for every person who wants to lose weight.
Zepbound is the weight-management product name for tirzepatide. Its April 2026 label covers long-term weight reduction for adults with obesity. It also covers adults with overweight and at least one weight-related condition. Zepbound has a separate use for moderate to severe obstructive sleep apnea in adults with obesity. This does not mean every person seeking weight loss has sleep apnea or will get the same result.
Saxenda is the weight-management product name for liraglutide. Its February 2026 label covers adults and patients aged 12 years and older who weigh more than 60 kilograms and have obesity. It also covers adults with overweight and a weight-related condition. FDA approved a first generic that refers to Saxenda in August 2025. That approval does not confirm pharmacy supply, coverage, or price.
Imcivree is setmelanotide. It activates the melanocortin-4 receptor, a protein that receives body signals. Its April 2026 label covers people aged 4 years and older with acquired hypothalamic obesity. It also covers people aged 2 years and older with Bardet-Biedl syndrome. The label covers rare forms caused by changes in three genes: POMC, PCSK1, or LEPR. It does not cover common obesity or other types outside these conditions.
04
How to compare approved products without choosing a “best” one.
First ask whether the exact product has an approved weight-reduction use for the relevant group. Then check whether its form matches what is being offered. Check the current reasons not to use it, warnings, drug interactions, and follow-up needs. An advertisement can highlight an average result while hiding the product name and label. This leaves out the most important context.
Percentages from different trials do not create a fair ranking. Trials can differ in who joined, starting risk, lifestyle support, length, missing data, and treatment stopping. They can also measure different results. Direct comparisons are more useful, but they still apply only to the products, groups, and periods studied.
Safety warnings differ by product. The Wegovy, Zepbound, and Saxenda labels warn about a type of thyroid-cell tumor found in rodents. It is not known whether this applies to people. The labels say not to use them with a personal or family history of medullary thyroid carcinoma, a type of cancer. They also name multiple endocrine neoplasia syndrome type 2, a rare inherited condition. The labels describe digestive-system side effects and other warnings.
Imcivree has different warnings because it is used in different people. These examples are not a full safety review or injection guide. Read the current FDA label and patient guide for the exact product.
A quoted fee may leave out medicine, visits, tests, shipping, supplies, or follow-up. Check each service and the exact product before you compare totals. This guide cannot confirm current price, coverage, or availability.
05
Still being studied: human research is not approval.
Retatrutide is still being studied. It acts on receptors for three body signals: GIP, GLP-1, and glucagon. A receptor is a protein that receives a body signal. A reviewed phase 2 trial enrolled 338 adults with obesity or overweight plus a related condition. The study followed treatment for 48 weeks.
The trial found more weight reduction at higher doses. It also found digestive-system side effects and heart-rate increases that rose with dose. This is meaningful human outcome evidence. It is not a completed FDA review of benefits and risks. It does not create an FDA-approved retail product.
ClinicalTrials.gov lists TRIUMPH-1, a late-stage phase 3 study, as completed. The record lists 2,335 participants and no summary results. An early summary from a sponsor does not replace a complete peer-reviewed report, FDA review, or approved label. A planned submission does not guarantee approval or launch.
Cagrilintide is a long-acting version of the body signal amylin. A published mid-stage study tested cagrilintide alone. A later large study tested cagrilintide with semaglutide in adults with overweight or obesity. These records show that researchers have studied cagrilintide in people. They do not make cagrilintide or the investigational combination called “CagriSema” FDA-approved.
FDA says retatrutide and cagrilintide cannot be used to make compounded drugs. Neither is a component of an FDA-approved drug. FDA has not found either one safe and effective for any condition. An online product is not proven to match material used in a clinical trial.
06
A compounded product is not the approved product in a new package.
Federal law has two main paths. Under section 503A, a pharmacy generally makes a compounded drug for one named patient. Under section 503B, an outsourcing facility can make batches if it meets legal rules. Neither path makes a compounded drug FDA-approved.
FDA does not review compounded drugs for safety, effectiveness, or quality before sale. Results from approved-product trials do not automatically apply. A prescription does not make a compounded drug an FDA-approved generic. Compounded and generic drugs follow different rules.
This difference became important during shortages. Consumers saw different vials, strengths, salt forms, and telehealth offers. FDA now states that semaglutide and tirzepatide do not appear on its drug-shortage list. FDA also reminds pharmacies and facilities that federal rules restrict copies of available drugs. Limited cases can involve a documented clinical difference for one named patient. A marketing page cannot prove that a product qualifies.
FDA has received reports of unwanted events linked to compounded semaglutide and tirzepatide. One report does not prove that a product caused the event. As of May 31, 2026, FDA had received 990 reports linked to compounded semaglutide. It had received more than 730 linked to compounded tirzepatide. Many state-licensed pharmacies do not have to report these events to FDA. The reports do not show a dependable rate because the total number of uses is not known. Do not compare them directly with rates from approved-product trials.
Product problems include measuring errors, different strengths and containers, dose increases that do not follow the label, shipping-temperature complaints, and false labels. They also include semaglutide sodium or acetate. FDA says these salt forms are different active ingredients from the semaglutide in approved drugs. FDA lacks information showing the same chemistry or effects in the body. A website's “same active ingredient” claim cannot resolve these differences.
07
Popular fat-loss peptides: different evidence, different limits.
AOD-9604 is often marketed as a fat-loss fragment of human growth hormone. FDA's 2024 review found that most studies did not show a weight-reduction benefit compared with placebo. A placebo is an inactive comparison. One study enrolled 536 people with obesity and did not find significant weight loss. The obesity development program ended after that failed study. Human exposure does not prove a meaningful benefit.
CJC-1295 and ipamorelin are often sold alone or in blends with body-composition claims. Studies in people can show body changes, such as growth-hormone levels. These changes do not prove lasting fat loss, better function, or that long-term benefits are greater than risks.
FDA says that clinical data for CJC-1295 are limited. FDA also identifies serious unwanted events linked to it. For ipamorelin acetate, FDA raises concerns about immune reactions and whether its identity and contents were fully confirmed. FDA cites serious events, including death, in a study where ipamorelin entered a vein to study stomach movement. That way into the body and study purpose do not show the risk for weight-loss injections. FDA says safety data for some other injection methods are absent.
MOTS-c is promoted with claims about metabolism and longer life. FDA says it has not found data from people who received drug products containing MOTS-c. It found no such data for any way the product entered the body. Findings from body mechanisms, cells, or animals cannot establish weight loss in people. A substance record, patent, or clinic menu is not a health result or FDA approval.
Do not put all these molecules in one “investigational” group. That word describes products still being studied. “Unapproved” describes FDA status. Neither word tells you how much evidence exists. Keep separate groups for controlled human outcomes, body changes in people, animal or cell findings, failed programs, and no reliable human drug-product evidence.
08
Peptide supplements are a separate category.
A product labeled “peptides” and taken by mouth might contain collagen pieces, broken-down proteins, or other dietary ingredients. It is not a version of Wegovy, Zepbound, Saxenda, Imcivree, retatrutide, or another injected drug. The ingredients, how the body takes them in, product form, use, and evidence differ.
FDA does not approve dietary supplements for safety and effectiveness before sale. A claim such as “supports metabolism” does not show useful weight loss. FDA also warns that weight-loss products are often part of health fraud. Some have contained hidden drug ingredients. A product missing from a warning list is not proven safe or effective.
When a supplement cites “peptide science,” check whether the study tested that exact product and measured weight change in people. Evidence from an injection, a single protein, or a meal-replacement plan does not automatically apply. A similar word on the label is not enough.
09
Questions to ask about any peptide weight-loss offer.
A sales page should name the exact product and the evidence behind its claim. A broad term such as “GLP-1,” “peptide therapy,” or “clinically proven” is not enough. The page should name the product, its form, its maker, and its FDA status. A clinic name can hide who made or gave out a compounded drug.
Before you compare offers, identify the product type and note missing facts. Use the current FDA label for an approved medicine. Do not call a compounded drug approved or generic. Do not assume it is equal to an approved product. A trial listing is not a result, and a result is not approval. For supplements, look for studies of the exact product in people.
Keep evidence separate from service terms. Check the full ongoing cost, included services, later price changes, cancellation, follow-up, prescriber, and dispenser. This check does not recommend a clinic or replace a medical assessment.
- What exact product, formulation, and regulatory category is being offered?
- Which current FDA label or primary trial supports the exact claim?
- Does the evidence match the population, outcome, and time horizon being advertised?
- If compounded, who is the actual compounder, and does the page avoid implying FDA approval, generic status, or automatic equivalence?
- If investigational or research-labeled, does the seller wrongly turn a study name into a consumer product claim?
- What is included in the total recurring price, and which costs, coverage decisions, or availability questions remain unresolved?
- Is a licensed clinician conducting a real assessment and available for product-specific safety questions and follow-up?
Common questions
Frequently asked questions
They include Wegovy (semaglutide), Zepbound (tirzepatide), Saxenda, a generic liraglutide product, and Imcivree (setmelanotide). Imcivree has a narrow use. Each approval covers one product and the use on its FDA label. It does not cover every item sold with the same ingredient name.
No. Researchers are still studying retatrutide, and FDA has not approved it. FDA says it is not part of an approved drug and federal law does not allow its use in compounding. FDA has not found it safe and effective for any condition. An online product might not match the product used in a trial.
No. A compounded drug does not have FDA approval. FDA does not review it for safety, effectiveness, and quality before sale. Results for Wegovy do not automatically apply to it. FDA also says semaglutide sodium and acetate differ from the active ingredient in approved drugs.
A useful weight-loss benefit is not proven. FDA found that most studies did not show more benefit than a placebo, an inactive comparison. One study included 536 people with obesity. It did not find a weight-loss difference that was unlikely to be due to chance. FDA also found safety gaps and doubts about the contents of compounded AOD-9604.
The word “peptide” does not show this. Supplements can contain collagen pieces or other food ingredients. They are not versions of prescription peptide medicines taken by mouth. FDA does not approve supplements for safety and effectiveness before sale. A weight-loss claim needs results from people who used the exact product.
First name the exact product, its form, FDA status, maker, and current label or main study. Then compare the full ongoing cost, included services, follow-up, coverage, and supply. A shared ingredient name, study record, prescription, or claim does not prove FDA approval. It also does not prove that two products are the same.
Sources